KFDA intention misinterpreted, say officials

Rejecting media reports, the Korea Food and Drug Administration said recently that it did not intend to side with latecomers, such as Daewoong and Yuhan Corp. in the controversial issue involving omission of clinical trials on novel amodipine salts, following the expiration of Pfizer's amlodipine patent. Three local generic makers Chong Kun Dang, Kolon Pharm and Hanmi, conducted their own cli...